Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis

Journal of Neuropathology and Experimental Neurology

Volumn 65, Issue 1, 2006, Pages 26-36

  Brockington, Alice ^a   Wharton, Stephen B ^a   Fernando, Malee ^a   Gelsthorpe, Catherine H ^a   Baxter, Lynne ^a   Ince, Paul G ^a   Lewis, Claire E ^a   Shaw, Pamela J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis (ALS); Immunohistochemistry; Motor neuron disease (MND); Neuropilin 1 (NRP1); Vascular endothelial growth factor (VEGF); VEGF receptor 2 (VEGFR2)

Indexed keywords

NEUROPILIN 1; SYNAPTOPHYSIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN A;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTERIOR HORN CELL; ARTICLE; AUTOCRINE EFFECT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MALE; MOTOR NEURON DISEASE; NERVE DEGENERATION; NEUROPIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPINAL CORD MOTONEURON; SYNAPTIC TRANSMISSION; TRANSGENIC MOUSE; WESTERN BLOTTING; CADAVER; COMPARATIVE STUDY; GENE EXPRESSION; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PHYSIOLOGY;

AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; BLOTTING, WESTERN; CENTRAL NERVOUS SYSTEM; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POSTMORTEM CHANGES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33644913172     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000196134.51217.74     Document Type: Article

References (32)

1. Figlewicz DA, Krizus A, Martinoli MG, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994;3:1757-61
2. Puls I, Jonnakuty C, LaMonte BH, et al. Mutant dynactin in motor neuron disease. Nat Genet 2003;33:455-56
3. Hadano S, Hand CK, Osuga H, et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 2001;29:166-73
4. Yang Y, Hentati A, Deng HX, et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 2001;29:160-65
5. Chen YZ, Bennett CL, Huynh HM, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 2004;74:1128-35
6. Nishimura AL, Mitne-Neto M, Silva HC, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 2004;75:822-31
7. Shaw PJ. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry 2005;76:1046-57
8. Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004;27:723-49
9. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76
10. Levy AP, Levy NS, Wegner S, et al. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995;270:13333-40
11. Liu Y, Cox SR, Morita T, et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 1995;77:638-43
12. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28:131-38
13. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-94
14. Brockington A, Kirby J, Eggitt D, et al. Screening of the regulatory and coding regions of vascular endothelial growth factor in amyotrophic lateral sclerosis. Neurogenetics 2004;6:101-4
15. Brockington A, Lewis C, Wharton S, et al. Vascular endothelial growth factor and the nervous system. Neuropathol Appl Neurobiol 2004;30:427-46
16. Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci U S A 1998;95:15809-14
17. Monacci WT, Merrill MJ, Oldfield EH. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol 1993;264:C995-C1002
18. Yang SZ, Zhang LM, Huang YL, et al. Distribution of Flk-1 and Flt-1 receptors in neonatal and adult rat brains. Anat Rec 2003;274A:851-56
19. Issa R, Krupinski J, Bujny T, et al. Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke. Lab Invest 1999;79:417-25
20. Spliet WG, Aronica E, Ramkema M, et al. Immunohistochemical localization of vascular endothelial growth factor receptors-1, -2 and -3 in human spinal cord: Altered expression in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 2004;30:351-59
21. Li B, Xu W, Luo C, et al. VEGF-induced activation of the PI3-K/Akt pathway reduces mutant SOD1-mediated motor neuron cell death. Brain Res Mol Brain Res 2003;111:155-64
22. Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005;8:85-92
23. Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004;429:413-17
24. Sopher BL, Thomas PS, LaFevre-Bernt MA, et al. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in motor neuron degeneration. Neuron 2004;41:687-91
25. Devos D, Moreau C, Lassalle P, et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology 2004;62:2127-29
26. Ince PG, Slade J, Chinnery RM, et al. Quantitative study of synaptophysin immunoreactivity of cerebral cortex and spinal cord in motor neuron disease. J Neuropathol Exp Neurol 1995;54:673-79
27. Lin RC, Scheller RH. Mechanisms of synaptic vesicle exocytosis. Annu Rev Cell Dev Biol 2000;16:19-24
28. Shimohama S, Kamiya S, Taniguchi T, et al. Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer's disease. Biochem Biophys Res Commun 1997;236:239-42
29. Ikemoto A, Nakamura S, Akiguchi I, et al. Differential expression between synaptic vesicle proteins and presynaptic plasma membrane proteins in the anterior horn of amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 2002;103:179-87
30. Cobbs CS, Chen J, Greenberg DA, et al. Vascular endothelial growth factor expression in transient focal cerebral ischemia in the rat. Neurosci Lett 1998;249:79-82
31. Vaquero J, Zurita M, de Oya S, et al. Vascular endothelial growth/permeability factor in spinal cord injury. J Neurosurg 1999;90:220-23
32. Silverman WF, Krum JM, Mani N, et al. Vascular, glial and neuronal effects of vascular endothelial growth factor in mesencephalic expiant cultures. Neuroscience 1999;90:1529-41